Literature DB >> 307455

Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team.

.   

Abstract

A large outbreak of haemorrhagic fever (subsequently named Ebola haemorrhagic fever) occurred in southern Sudan between June and November 1976. There was a total of 284 cases; 67 in the source town of Nzara, 213 in Maridi, 3 in Tembura, and 1 in Juba. The outbreak in Nzara appears to have originated in the workers of a cotton factory. The disease in Maridi was amplified by transmission in a large, active hospital. Transmission of the disease required close contact with an acute case and was usually associated with the act of nursing a patient. The incubation period was between 7 and 14 days. Although the link was not well established, it appears that Nzara could have been the source of infection for a similar outbreak in the Bumba Zone of Zaire.In this outbreak Ebola haemorrhagic fever was a unique clinical disease with a high mortality rate (53% overall) and a prolonged recovery period in those who survived. Beginning with an influenza-like syndrome, including fever, headache, and joint and muscle pains, the disease soon caused diarrhoea (81%), vomiting (59%), chest pain (83%), pain and dryness of the throat (63%), and rash (52%). Haemorrhagic manifestations were common (71%), being present in half of the recovered cases and in almost all the fatal cases.Two post mortems were carried out on patients in November 1976. The histopathological findings resembled those of an acute viral infection and although the features were characteristic they were not exclusively diagnostic. They closely resembled the features described in Marburg virus infection, with focal eosinophilic necrosis in the liver and destruction of lymphocytes and their replacement by plasma cells. One case had evidence of renal tubular necrosis.Two strains of Ebola virus were isolated from acute phase sera collected from acutely ill patients in Maridi hospital during the investigation in November 1976. Antibodies to Ebola virus were detected by immunofluorescence in 42 of 48 patients in Maridi who had been diagnosed clinically, but in only 6 of 31 patients in Nzara. The possibility of the indirect immunofluorescent test not being sufficiently sensitive is discussed.Of Maridi case contacts, in hospital and in the local community, 19% had antibodies. Very few of them gave any history of illness, indicating that Ebola virus can cause mild or even subclinical infections. Of the cloth room workers in the Nzara cotton factory, 37% appeared to have been infected, suggesting that the factory may have been the prime source of infection.

Entities:  

Mesh:

Year:  1978        PMID: 307455      PMCID: PMC2395561     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

1.  Fatal human disease from vervet monkeys.

Authors:  C E Smith; D I Simpson; E T Bowen; I Zlotnik
Journal:  Lancet       Date:  1967-11-25       Impact factor: 79.321

2.  Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972.

Authors:  P E Mertens; R Patton; J J Baum; T P Monath
Journal:  Am J Trop Med Hyg       Date:  1973-11       Impact factor: 2.345

3.  A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972.

Authors:  T P Monath; P E Mertens; R Patton; C R Moser; J J Baum; L Pinneo; G W Gary; R E Kissling
Journal:  Am J Trop Med Hyg       Date:  1973-11       Impact factor: 2.345

4.  Lassa fever. Epidemiological aspects of the 1970 epidemic, Jos, Nigeria.

Authors:  D E Carey; G E Kemp; H A White; L Pinneo; R F Addy; A L Fom; G Stroh; J Casals; B E Henderson
Journal:  Trans R Soc Trop Med Hyg       Date:  1972       Impact factor: 2.184

5.  Indirect immunofluorescence for the diagnosis of Lassa fever infection.

Authors:  H Wulff; J V Lange
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

6.  Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire.

Authors:  K M Johnson; J V Lange; P A Webb; F A Murphy
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

7.  Viral haemorrhagic fever in southern Sudan and northern Zaire. Preliminary studies on the aetiological agent.

Authors:  E T Bowen; G Lloyd; W J Harris; G S Platt; A Baskerville; E E Vella
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

8.  A critical study of monkey sera for the presence of antibody against the Marburg virus.

Authors:  W Slenczka; G Wolff; R Siegert
Journal:  Am J Epidemiol       Date:  1971-06       Impact factor: 4.897

9.  An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report.

Authors:  J M Troup; H A White; A L Fom; D E Carey
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

10.  The neuropathology of an infectious disease transmitted by African green monkeys (Cercopithecus aethiops).

Authors:  H Bechtelsheimer; H Jacob; H Solcher
Journal:  Ger Med Mon       Date:  1969-01
View more
  194 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoprotein.

Authors:  Tetsuro Ikegami; Masahiro Niikura; Masayuki Saijo; Mary E Miranda; Alan B Calaor; Marvin Hernandez; Luz P Acosta; Daria L Manalo; Ichiro Kurane; Yasuhiro Yoshikawa; Shigeru Morikawa
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 3.  Clinical development of Ebola vaccines.

Authors:  Saranya Sridhar
Journal:  Ther Adv Vaccines       Date:  2015-09

Review 4.  Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins.

Authors:  Masayuki Saijo; Masahiro Niikura; Tetsuro Ikegami; Ichiro Kurane; Takeshi Kurata; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2006-04

5.  Understanding the dynamics of Ebola epidemics.

Authors:  J Legrand; R F Grais; P Y Boelle; A J Valleron; A Flahault
Journal:  Epidemiol Infect       Date:  2006-09-26       Impact factor: 2.451

6.  Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.

Authors:  Akihito Yonezawa; Marielle Cavrois; Warner C Greene
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 7.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

8.  Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

Authors:  Anita K McElroy; Jessica R Harmon; Timothy D Flietstra; Shelley Campbell; Aneesh K Mehta; Colleen S Kraft; Marshall G Lyon; Jay B Varkey; Bruce S Ribner; Christopher J Kratochvil; Peter C Iwen; Philip W Smith; Rafi Ahmed; Stuart T Nichol; Christina F Spiropoulou
Journal:  Clin Infect Dis       Date:  2016-06-27       Impact factor: 9.079

9.  Discovery and Description of Ebola Zaire Virus in 1976 and Relevance to the West African Epidemic During 2013-2016.

Authors:  Joel G Breman; David L Heymann; Graham Lloyd; Joseph B McCormick; Malonga Miatudila; Frederick A Murphy; Jean-Jacques Muyembé-Tamfun; Peter Piot; Jean-François Ruppol; Pierre Sureau; Guido van der Groen; Karl M Johnson
Journal:  J Infect Dis       Date:  2016-06-29       Impact factor: 5.226

Review 10.  Epidemiology and Management of the 2013-16 West African Ebola Outbreak.

Authors:  M L Boisen; J N Hartnett; A Goba; M A Vandi; D S Grant; J S Schieffelin; R F Garry; L M Branco
Journal:  Annu Rev Virol       Date:  2016-08-15       Impact factor: 10.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.